Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Oncotarget, 7, 15, S. 20033-20040
- Ereignis
-
Veröffentlichung
- (wo)
-
Augsburg
- (wer)
-
Universität Augsburg
- (wann)
-
2016
- Ereignis
-
Veröffentlichung
- (wer)
-
Impact Journals, LLC
- (wann)
-
2016
- Urheber
-
Lapa, Constantin Frederik Victor
Hänscheid, Heribert
Wild, Vanessa
Pelzer, Theo
Schirbel, Andreas
Wolf, Herta
Droll, Sabine
Herrmann, Ken
Buck, Andreas K.
Lückerath, Katharina
- DOI
-
10.18632/oncotarget.7706
- URN
-
urn:nbn:de:bvb:384-opus4-634505
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:49 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lapa, Constantin Frederik Victor
- Hänscheid, Heribert
- Wild, Vanessa
- Pelzer, Theo
- Schirbel, Andreas
- Wolf, Herta
- Droll, Sabine
- Herrmann, Ken
- Buck, Andreas K.
- Lückerath, Katharina
- Universität Augsburg
- Impact Journals, LLC
Entstanden
- 2016
Ähnliche Objekte (12)
Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
Pre-therapy Somatostatin-Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy
Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
Paralytic subileus as an adverse effect of amino acid–based nephroprotection in a patient undergoing peptide receptor radionuclide therapy
Pretherapeutic estimation of kidney function in patients treated with peptide receptor radionuclide therapy: can renal scintigraphy be safely omitted?
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Imaging of myocardial inflammation with somatostatin receptor based PET/CT: a comparison to cardiac MRI
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Ein 18F markiertes PET-Radiopharmakon (LMI1195) zur Bildgebung des Norepinephrin-Stoffwechsels im Rattenherz
Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
Pre-therapy Somatostatin-Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy
Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
Paralytic subileus as an adverse effect of amino acid–based nephroprotection in a patient undergoing peptide receptor radionuclide therapy
Pretherapeutic estimation of kidney function in patients treated with peptide receptor radionuclide therapy: can renal scintigraphy be safely omitted?
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Imaging of myocardial inflammation with somatostatin receptor based PET/CT: a comparison to cardiac MRI
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Ein 18F markiertes PET-Radiopharmakon (LMI1195) zur Bildgebung des Norepinephrin-Stoffwechsels im Rattenherz
Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
Pre-therapy Somatostatin-Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy
Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
Paralytic subileus as an adverse effect of amino acid–based nephroprotection in a patient undergoing peptide receptor radionuclide therapy
Pretherapeutic estimation of kidney function in patients treated with peptide receptor radionuclide therapy: can renal scintigraphy be safely omitted?
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Imaging of myocardial inflammation with somatostatin receptor based PET/CT: a comparison to cardiac MRI
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy